TY - JOUR T1 - Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 144 LP - 148 DO - 10.1136/ijgc-00009577-200311001-00003 VL - 13 IS - Suppl 2 AU - M. J. Piccart AU - K. Bertelsen AU - G. Stuart AU - J. Cassidy AU - C. Mangioni AU - E. Simonsen AU - K. James AU - S. Kaye AU - I. Vergote AU - R. Blom AU - R. Grimshaw AU - R. Atkinson AU - K. Swenerton AU - C. Trope AU - M. Nardi AU - J. Kaern AU - S. Tumolo AU - P. Timmers AU - J.-A. Roy AU - F. Lhoas AU - B. Lidvall AU - M. Bacon AU - A. Birt AU - J. Andersen AU - B. Zee AU - J. Paul AU - S. Pecorelli AU - B. Baron AU - W. Mcguire Y1 - 2003/10/01 UR - http://ijgc.bmj.com/content/13/Suppl_2/144.abstract N2 - Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer. ER -